Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adoptive Cell Therapy for Nonhematologic Solid Tumors
Daniel J. Olson, Kunle Odunsi
Journal of Clinical Oncology (2023) Vol. 41, Iss. 18, pp. 3397-3407
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Current understanding and management of CAR T cell-associated toxicities
Jennifer N. Brudno, James N. Kochenderfer
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 501-521
Closed Access | Times Cited: 60
CD8+ T cell-based cancer immunotherapy
Yanxia Chen, Dingning Yu, Hui Qian, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 24
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies
John B.A.G. Haanen, Christy Los, Giao Q. Phan, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 10
CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors
Jiahao Liu, Xiaofei Jiao, Ding Ma, et al.
Med (2024) Vol. 5, Iss. 6, pp. 530-549
Closed Access | Times Cited: 9
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies
Minghua Xiang, Huayi Li, Yuanyuan Zhan, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access | Times Cited: 1
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 527-548
Closed Access | Times Cited: 6
Adopting tomorrow’s therapies today: a perspective review of adoptive cell therapy in lung cancer
Faith Abodunrin, Daniel J. Olson, Oluwatosin Emehinola, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
The Clinical TIL Experience in Melanoma: Past, Present, Future
James W. Smithy, Adam J. Schoenfeld, Allison Betof Warner
Transplantation and Cellular Therapy (2025) Vol. 31, Iss. 3, pp. S626-S634
Open Access
Construction of In Situ Personalized Cancer Vaccines by Bioorthogonal Catalytic Microneedles for Augmented Melanoma Immunotherapy
Qianhe Xu, Xiu‐Yuan Yin, Z. Chen, et al.
Small (2025)
Closed Access
Transcript-targeted antigen mapping reveals the potential of POSTN splicing junction epitopes in glioblastoma immunotherapy
Zujian Xiong, Chaim Sneiderman, Chloe R Kuminkoski, et al.
Genes and Immunity (2025)
Closed Access
Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges
Jun-Jie Liu, Mi Zhou, Tong Yuan, et al.
World Journal of Gastroenterology (2025) Vol. 31, Iss. 15
Closed Access
Unlocking tumor-infiltrating lymphocyte potential with CRISPR-Cas9
Özcan Met, Inge Marie Svane
The Lancet Oncology (2025) Vol. 26, Iss. 5, pp. 530-531
Closed Access
Glory Days: Celebrating Two Decades of Advances in Cancer Care on the 20th Anniversary of JCO Oncology Practice
Jeffrey Peppercorn, Douglas W. Blayney, Linda D. Bosserman, et al.
JCO Oncology Practice (2025) Vol. 21, Iss. 5, pp. 581-586
Closed Access
Organ-on-a-chip models for development of cancer immunotherapies
M. Chernyavska, Mina Masoudnia, Thomas Valerius, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 12, pp. 3971-3983
Open Access | Times Cited: 9
High-throughput CRISPR technology: a novel horizon for solid organ transplantation
Xiaohan Li, Zhang Chen, Weicong Ye, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 3
Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC
Evangelia Bogatsa, George Lazaridis, Chrysoula Stivanaki, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1619-1619
Open Access | Times Cited: 2
Alginate-based artificial antigen presenting cells expand functional CD8+ T cells with memory characteristics for adoptive cell therapy
Mary O. Omotoso, Savannah Est-Witte, Sydney R. Shannon, et al.
Biomaterials (2024) Vol. 313, pp. 122773-122773
Closed Access | Times Cited: 2
Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy
Zhouchi Yao, Yayun Zeng, Cheng Liu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
Augmentation of Solid Tumor Immunotherapy With IL‐12
Christian Geils, Katie L. Kathrein
The Journal of Gene Medicine (2024) Vol. 26, Iss. 12
Closed Access | Times Cited: 2
Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma
Abraham L. Bayer, Darwing Padilla-Rolon, Sasha Smolgovsky, et al.
American Journal Of Pathology (2024) Vol. 194, Iss. 6, pp. 1007-1019
Closed Access | Times Cited: 1
Construction of an Innovative Nanogel and Its Applications for Achieving Chemo-Immunotherapy of Tumors
Sibei Wang, Fan Nie, Zhen Lin, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 44, pp. 59895-59906
Closed Access | Times Cited: 1
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies
Luigi Liguori, Fabio Salomone, Angela Viggiano, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 205, pp. 104554-104554
Open Access | Times Cited: 1
Advances and considerations in the use of immunotherapies for primary hepato-biliary malignancies
Leva Gorji, Zachary J. Brown, Timothy M. Pawlik
Surgical Oncology (2023) Vol. 52, pp. 102031-102031
Closed Access | Times Cited: 2
One signal activated TIL enable potent anti-tumor activity across diverse solid tumor types
Yongqiang Wu, Xueshuai Ye, Yufeng Zhu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top